These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 27987593)

  • 1. Clinical course of stage IV invasive mucinous adenocarcinoma of the lung.
    Cha YJ; Kim HR; Lee HJ; Cho BC; Shim HS
    Lung Cancer; 2016 Dec; 102():82-88. PubMed ID: 27987593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis in Resected Invasive Mucinous Adenocarcinomas of the Lung: Related Factors and Comparison with Resected Nonmucinous Adenocarcinomas.
    Lee HY; Cha MJ; Lee KS; Lee HY; Kwon OJ; Choi JY; Kim HK; Choi YS; Kim J; Shim YM
    J Thorac Oncol; 2016 Jul; 11(7):1064-73. PubMed ID: 27016260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma.
    Luo J; Wang R; Han B; Zhang J; Zhao H; Fang W; Luo Q; Yang J; Yang Y; Zhu L; Chen T; Cheng X; Huang Q; Wang Y; Zheng J; Chen H
    J Cancer Res Clin Oncol; 2016 Aug; 142(8):1837-45. PubMed ID: 27342421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the immunotherapy efficacy between invasive mucinous and non-mucinous adenocarcinoma in advanced lung cancer patients with KRAS mutation: a retrospective study.
    Xu M; Hao Y; Zhou H; Shi Z; Si J; Song Z
    Med Oncol; 2023 Jun; 40(7):198. PubMed ID: 37294384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary Invasive Mucinous Adenocarcinoma of the Lung: Prognostic Value of CT Imaging Features Combined with Clinical Factors.
    Wang T; Yang Y; Liu X; Deng J; Wu J; Hou L; Wu C; She Y; Sun X; Xie D; Chen C
    Korean J Radiol; 2021 Apr; 22(4):652-662. PubMed ID: 33236544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive mucinous adenocarcinoma of the lung: Serial CT findings, clinical features, and treatment and survival outcomes.
    Beck KS; Sung YE; Lee KY; Han DH
    Thorac Cancer; 2020 Dec; 11(12):3463-3472. PubMed ID: 33021074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis of resected invasive mucinous adenocarcinoma compared with the IASLC histologic grading system for invasive nonmucinous adenocarcinoma: Surgical database study in the TKIs era in Korea.
    Woo W; Yang YH; Cha YJ; Moon DH; Shim HS; Cho A; Kim BJ; Kim HE; Park BJ; Lee JG; Kim DJ; Paik HC; Lee S; Lee CY
    Thorac Cancer; 2022 Dec; 13(23):3310-3321. PubMed ID: 36345148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaplastic lymphoma kinase fusion protein expression is associated with a favorable prognosis in resected invasive mucinous lung adenocarcinoma: A retrospective study from two Chinese tertiary hospitals.
    Wang J; Wei P; Liu J; Su P; Xing A; Jing H; Hao J
    J Cancer Res Ther; 2022 Apr; 18(2):445-451. PubMed ID: 35645113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy.
    Chang S; Hur J; Hong YJ; Lee HJ; Kim YJ; Han K; Choi BW
    AJR Am J Roentgenol; 2018 Jan; 210(1):43-51. PubMed ID: 29091002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Surgical Outcomes Between Invasive Mucinous and Non-Mucinous Lung Adenocarcinoma.
    Matsui T; Sakakura N; Koyama S; Nakanishi K; Sasaki E; Kato S; Hosoda W; Murakami Y; Kuroda H; Yatabe Y
    Ann Thorac Surg; 2021 Oct; 112(4):1118-1126. PubMed ID: 33242433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing clinicopathological features and prognosis of primary pulmonary invasive mucinous adenocarcinoma based on computed tomography findings.
    Nie K; Nie W; Zhang YX; Yu H
    Cancer Imaging; 2019 Jul; 19(1):47. PubMed ID: 31292000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung.
    Ueda D; Ito M; Tsutani Y; Giménez-Capitán A; Román-Lladó R; Pérez-Rosado A; Aguado C; Kushitani K; Miyata Y; Arihiro K; Molina-Vila MA; Rosell R; Takeshima Y; Okada M
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3709-3718. PubMed ID: 33796913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).
    Sarosi V; Losonczy G; Francovszky E; Tolnay E; Torok S; Galffy G; Hegedus B; Dome B; Ostoros G
    Lung Cancer; 2014 Oct; 86(1):54-8. PubMed ID: 25129367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive mucinous adenocarcinoma of the lung: clinicopathological features,
    Sun X; Zeng B; Tan X; Chen Z; Pan X; Jiang L
    Ann Nucl Med; 2023 Mar; 37(3):198-207. PubMed ID: 36538165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.
    Nakaoku T; Tsuta K; Ichikawa H; Shiraishi K; Sakamoto H; Enari M; Furuta K; Shimada Y; Ogiwara H; Watanabe S; Nokihara H; Yasuda K; Hiramoto M; Nammo T; Ishigame T; Schetter AJ; Okayama H; Harris CC; Kim YH; Mishima M; Yokota J; Yoshida T; Kohno T
    Clin Cancer Res; 2014 Jun; 20(12):3087-93. PubMed ID: 24727320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acinar-Predominant Pattern Correlates With Poorer Prognosis in Invasive Mucinous Adenocarcinoma of the Lung.
    Lin G; Li H; Kuang J; Tang K; Guo Y; Han A; Xie C
    Am J Clin Pathol; 2018 Mar; 149(5):373-378. PubMed ID: 29538611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
    Hurbin A; Wislez M; Busser B; Antoine M; Tenaud C; Rabbe N; Dufort S; de Fraipont F; Moro-Sibilot D; Cadranel J; Coll JL; Brambilla E
    J Pathol; 2011 Sep; 225(1):83-95. PubMed ID: 21598249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
    Yang CJ; Tsai MJ; Hung JY; Lee MH; Tsai YM; Tsai YC; Hsu JF; Liu TC; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):82. PubMed ID: 29237484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiological and clinical features of screening-detected pulmonary invasive mucinous adenocarcinoma.
    Kim DH; Bae SY; Na KJ; Park S; Park IK; Kang CH; Kim YT
    Interact Cardiovasc Thorac Surg; 2022 Jan; 34(2):229-235. PubMed ID: 34570199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiological and clinical features of large consolidative-type pulmonary invasive mucinous adenocarcinoma.
    Chen J; Qi L; Wang J; Xue L; Xue Q; Jia J; Zhang G; Liu J; Li F; Cui S
    Clin Respir J; 2024 Mar; 18(3):e13743. PubMed ID: 38529681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.